The only alcohol-free class 2 corticosteroid solution to help minimize burning and stinging1-4
NOW AVAILABLE
FOR BUSY BODIES WITH
CORTICOSTEROID-RESPONSIVE
DERMATOSES (CRD) SUCH AS:
- Scalp psoriasis
- Seborrheic dermatitis
A NON-IRRITATING ALCOHOL FREE FORMULATION1,2,5,6
HELP YOUR PATIENTS KEEP UP WITH THE DEMANDS OF THEIR DAY
Life doesn’t come with a pause button, and burning, stinging, and itching can be disruptive to busy modern-day lifestyles.7-9
Busy bodies need a treatment option that relieves itch without causing irritation or burning and stinging upon application.
THE ONLY ALCOHOL-FREE CLASS 2 CORTICOSTEROID SOLUTION TO HELP MINIMIZE BURNING AND STINGING1-4
HALOG® Solution (Halcinonide Topical Solution, USP) 0.1% is alcohol-free to help minimize burning and stinging while relieving itch and inflammation caused by corticosteroid-responsive dermatoses (CRD) such as scalp psoriasis and seborrheic dermatitis.1,2,6
Free of common irritating or allergenic ingredients1-2,6:
- No alcohol
- No propylene glycol
- No sulfates
- No parabens
- No fragrances
Cosmetically desirable for the scalp or hair-bearing areas5:
- Sodium lauryl sulfate-free to avoid damaging hair1,10
- Colorless and undetectable after application5
- Only 4 excipients1
PROVEN EFFICACY IN SCALP PSORIASIS IN AS LITTLE AS 2 WEEKS5
In a 2-week efficacy study, HALOG® Solution demonstrated superior efficacy in 81% of patients compared to 15% of patients using a placebo solution.5
CONTRAINDICATIONS1
Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of the preparations.
ADVERSE REACTIONS1
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
A class 2 treatment option without certain prescribing restrictions1,4,11
No restrictions based on1:
PATIENT AGE
Weekly Dosage Limits
Application to specific parts of the body
Body Surface Area
No generic equivalent!
Reinforce your decision to prescribe HALOG® Solution
by writing DAW-1 every time.
References: 1. HALOG® Solution [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2019. 2. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. 2nd ed. NY: Springer-Verlag Berlin Heidelberg; 2000. 3. Sun Pharmaceutical Industries, Inc. Data on File. 2020. 4. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140. 5. Lepaw MI. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis. 1978;21(4):571-573. 6. Scheman A. Adverse reactions to cosmetic ingredients. Dermatol Clin. 2000;18(4):685-698. 7. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–332. 8. Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33–40. 9. Hill D, Farhangian ME, Feldman SR. Increasing adherence to topical therapy in psoriasis through use of solution medication. Dermatol Online J. 2016;22(5):16. 10. Cline A, Uwakwe LN, McMichael AJ. No sulfates, no parabens, and the “no-poo” method: a new patient perspective on common shampoo ingredients. Cutis. 2018;101(1):22-26. 11. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017.
INDICATIONS AND USAGE
HALOG® Solution (Halcinonide Topical Solution, USP) 0.1%, HALOG (Halcinonide Cream, USP) 0.1% and HALOG (Halcinonide OINTMENT, USP) 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
PRECAUTIONS
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse Reactions
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.